ACADIA Pharmaceuticals Inc To Discuss Complete Response Letter from U.S. FDA for Supplemental New Drug Application Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Gregory James Renza - RBC Capital Markets, Research Division - Analyst : Just in relation to, of course, the focus on the Type A meeting and your efforts there, I'm just curious if you could comment on perhaps what else you can do or are planning to do with other aspects of the business and the development that is with just shoring up and ensuring the stability and growth of the commercial franchise as well as the other ongoing studies and how you intend to message and at least address the DRP developments in light of everything else that is happening in your business?

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : We know you believe underlying psychosis could be similar across subtypes, which appears like a fair contention. And you had included this information that I'm going to be asking about in your sNDA package, but could you remind us as to how pimavanserin performed in HARMONY, specifically in Alzheimer's patients, which is the largest fraction of patients within the DRP indication and how that information might specifically help your arguments as you head into a potential Type A meeting?